

Cover Story
FreeGuest Editorial
By Jhanelle E. Gray, Karen Reckamp, Mary Redman, Konstantin H. Dragnev, Ellen V. Sigal, Shakun Malik, Meg Mooney, James H. Doroshow and Charles D. Blanke
S2302 Pragmatica-Lung is a federally-funded, streamlined clinical trial examining a new combination of agents in patients with advanced non-small cell lung cancer (NSCLC). Like most studies, it is focused on improving outcomes for patients with cancer—but it is also poised to simplify and transform the entire clinical trials model as we know it.
Cancer History ProjectFree
By Alexandria Carolan and Katie Goldberg
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document - NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing - TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- AACI letter to NIH’s Bhattacharya opposes centralizing review of CCSG